Tariffs
The AHA today sent a letter to the Office of the United States Trade Representative to ask that medications, medical devices and other healthcare equipment and supplies be exempted from proposed duties on goods from other nations. While “America’s hospitals and health systems support…
The American Hospital Association (AHA) appreciates the opportunity to comment on the Office of the Trade Representative’s proposed duties on certain economies under section 301 of the Trade Act of 1974.
The U.S. Trade Representative yesterday announced plans to impose additional tariffs on goods from certain nations that it said had lacked or failed to enforce a ban on goods produced with forced labor. The agency reached the conclusion following an investigation under…
The White House April 2 issued a proclamation implementing additional tariffs on certain patented pharmaceutical products and ingredients.
This Costs of Caring report provides a data-driven assessment of the financial realities faced by hospitals and health systems, and underscores why sustainable affordability solutions must address the structural drivers of cost growth rather than focusing narrowly on hospital prices alone.
This report outlines the key trends impacting hospital financial stability in 2025.
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In exchange, the U.K. will increase the net price it pays for new medicines by 25%.
Executive Order 14257 Regulating Imports with a Reciprocal Tariff to Rectify Trade Practices that Contribute to Large and Persistent Annual United States Goods Trade Deficits imposes tariffs on all trading partners.
Executive Order 14257 Regulating Imports with a Reciprocal Tariff to Rectify Trade Practices that Contribute to Large and Persistent Annual United States Goods Trade Deficits imposes tariffs on all trading partners.
This order modifies tariff measures previously imposed pursuant to Executive Order 14195, Imposing Duties to Address the Synthetic Opioid Supply Chain in the People’s Republic of China.